Skip to main content

Table 1 Patient characteristics

From: Predictive and prognostic value of PET/CT imaging post-chemoradiotherapy and clinical decision-making consequences in locally advanced head & neck squamous cell carcinoma: a retrospective study

Characteristics Total (N = 78) Non-mCR (N = 37) mCR (N = 41) P-value
Age, median (range) 62 (24–79) 62 (24–76) 61 (42–79) 0.288
Sex, n (%)     
 Male 63 (80.8) 27 (73.0) 36 (87.8)  
 Female 15 (19.23) 10 (27.0) 5 (12.2) 0.097
ECOG PS, n (%)     
 0 19 (24.4) 8 (21.6) 11 (26.8)  
 1 58 (74.4) 28 (75.7) 30 (73.2)  
 2 1 (1.3) 1 (2.7) 0 (0.0) 0.601*
Location, n (%)     
 Oropharynx 47 (60.3) 19 (51.4) 28 (68.3)  
 Hypopharynx 19 (24.4) 11 (29.7) 8 (19.5)  
 Larynx 3 (3.9) 2 (5.4) 1 (2.4)  
 Oral cavity 5 (6.4) 4 (10.8) 1 (2.4)  
 Nasal cavity/PNS 1 (1.3) 0 (0.0) 1 (2.4)  
 Others 3 (3.9) 1 (2.7) 2 (4.9) 0.364*
Pathology, n (%)     
 Undifferentiated SCC 2 (2.6) 2 (5.4) 0 (0.0)  
 Poorly differentiated SCC 13 (16.7) 4 (10.8) 9 (22.0)  
 Moderately differentiated SCC 20 (25.6) 7 (18.9) 13 (31.7)  
 Well differentiated SCC 7 (9.0) 6 (16.2) 1 (2.4)  
 Nonkeratinizing carcinoma 1 (1.3) 1 (2.7) 18 (43.9)  
 Unknown/not specified SCC 35 (44.9) 17 (45.6) 0 (0.0) 0.058*
TNM Stage, n (%)     
 III 23 (29.5) 8 (21.6) 15 (36.6)  
 IVA 54 (69.2) 29 (78.4) 25 (61.0)  
 IVB 1 (1.3) 0 (0.0) 1 (2.4) 0.140*
IC, n (%) 50 (64.1) 25 (67.6) 25 (61.0)  
 FP 4 (5.1) 3 (8.1) 1 (2.4)  
 DFP 16 (20.5) 6 (16.2) 10 (24.4)  
 DP 26 (33.3) 14 (37.8) 12 (29.3)  
 DP + cetuximab 4 (5.1) 2 (5.4) 2 (4.9) 0.544
CRT regimen, n (%)     
 Cisplatin 71 (91.0) 33 (89.2) 38 (92.7)  
 Cetuximab 3 (3.9) 1 (2.7) 2 (4.9)  
 Cisplatin + cetuximab 3 (3.9) 2 (5.4) 1 (2.4)  
 Cisplatin + 5-FU 1 (1.3) 1 (2.7) 0 (0.0) 0.689*
Total radiation dose     
  > 60 Gy 80 (97.6) 38 (97.4) 42 (97.7)  
  ≤ 60 Gy 2 (2.4) 1 (2.6) 1 (2.3) 1.000*
Failure in six months, n (%) 10 (12.8) 10 (27.0) 0 (0.0) <0.001*
 Locoregional failure alone 9 (11.5) 9 (24.3) 0 (0.0)  
 Systemic & locoregional failure 1 (1.3) 1 (2.7) 0 (0.0)  
Immediate salvage op, n (%) 6 (7.7) 6 (16.2) 0 (0.0) 0.009*
  1. Abbreviations: mCR metabolic complete response, IC induction chemotherapy, CRT concurrent chemoradiotherapy, ECOG PS Eastern Cooperative Oncology Group performance status, SCC squamous cell carcinoma, FP 5-fluorouracil and cisplatin, DFP docetaxel, 5-fluorouracil and cisplatin, DP docetaxel and cisplatin, 5-FU 5-fluorouracil
  2. *Fisher’s exact test
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us